<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04054011</url>
  </required_header>
  <id_info>
    <org_study_id>181524</org_study_id>
    <nct_id>NCT04054011</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat</brief_title>
  <official_title>Safety and Efficacy of Deoxycholic Acid Injection for Reduction of Upper Inner Thigh Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, open-label clinical trial evaluating the safety and efficacy of&#xD;
      deoxycholic acid injection for reduction of upper inner thigh fat.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unwanted upper inner thigh fat is a common aesthetic complaint from patients, and current&#xD;
      treatment options include liposuction and cryolipolysis (CoolSculpting, Allergan, Irvine,&#xD;
      CA). Deoxycholic acid (Kybella, Allergan, Irvine, CA) is an FDA-approved injectable for the&#xD;
      treatment of excess submental fat. At this time, it is not known if deoxycholic acid may be a&#xD;
      safe and effective treatment for upper inner thigh fat. The proposed clinical trial will&#xD;
      evaluate the safety and efficacy of deoxycholic acid for reduction of upper inner thigh fat.&#xD;
&#xD;
      In this single-arm, open-label safety and efficacy study, 15 subjects with excess upper inner&#xD;
      thigh fat will receive 1-4 treatment sessions of subcutaneously injected deoxycholic acid.&#xD;
      Subjects will be followed for 12 weeks after last treatment. Adverse events will be&#xD;
      monitored. Efficacy will be objectively measured by change in thigh circumference; change in&#xD;
      upper inner thigh skin fold thickness; increase in &quot;thigh gap;&quot; and percent accuracy by three&#xD;
      blinded physicians in correctly identifying baseline photographs, upon independent review of&#xD;
      before-and-after clinical photographs of the treatment area. Patient satisfaction related to&#xD;
      the study treatment will be assessed with a Subject Self-Rating Scale throughout the study,&#xD;
      and with a Post-Treatment Satisfaction Questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 5, 2019</start_date>
  <completion_date type="Actual">May 19, 2020</completion_date>
  <primary_completion_date type="Actual">May 19, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All subjects will receive deoxycholic acid (1-4 treatment sessions) for treatment of upper inner thigh fat.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Baseline to 12 weeks after last treatment</time_frame>
    <description>Any adverse event (AE) ascertained by patient report or physician evaluation&#xD;
One or more serious adverse events (SAE) as defined by CTCAEv4&#xD;
Adverse events leading to study drug discontinuation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Thigh Circumference Change</measure>
    <time_frame>Baseline to 12 weeks after last treatment</time_frame>
    <description>change in thigh circumference as measured by tape measure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper Inner Thigh Skin Fold Thickness Change</measure>
    <time_frame>Baseline to 12 weeks after last treatment</time_frame>
    <description>change in upper inner thigh skin fold thickness as measured by body fat calipers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Thigh Gap</measure>
    <time_frame>12 weeks</time_frame>
    <description>Thigh gap,&quot; measured with a handheld soft ruler, was defined as the horizontal distance between baseline &quot;sites of maximum bulge,&quot; with feet at standardized distance apart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Accuracy by Three Blinded Physicians in Correctly Identifying Before-and-after Photographs</measure>
    <time_frame>12 weeks</time_frame>
    <description>3 blinded physicians identified the before and after photos and the percentage number was 83% for percent accuracy of the results. The percent accuracy was calculated for the entire Arm/Group rather than for each participant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Adiposity</condition>
  <arm_group>
    <arm_group_label>deoxycholic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deoxycholic Acid</intervention_name>
    <description>Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous</description>
    <arm_group_label>deoxycholic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged 18 to 65&#xD;
&#xD;
          2. Discrete area of mild-to-moderate excess upper inner thigh fat, amenable to treatment&#xD;
             at the discretion of the investigator&#xD;
&#xD;
          3. Subjects who score 0 (extremely dissatisfied) to 2 (slightly dissatisfied) on a&#xD;
             Subject Self-Rating Scale, pertaining to upper inner thigh fat, with the scale ranging&#xD;
             from 0 (extremely dissatisfied) to 6 (extremely satisfied)&#xD;
&#xD;
          4. Body mass index (BMI) less than 30 kg/m2&#xD;
&#xD;
          5. Stable body weight for previous 6 months (weight within 10 pounds of baseline)&#xD;
&#xD;
          6. Subjects must be in stable health, as confirmed by medical history, per investigator&#xD;
             judgment&#xD;
&#xD;
          7. Subjects must be able to read, sign, and understand the informed consent&#xD;
&#xD;
          8. Subjects must we willing to avoid any other treatments to the inner thigh, including&#xD;
             cryolipolysis and liposuction, during the study period.&#xD;
&#xD;
          9. Subjects must be willing to avoid changes in diet or exercise, any weight loss&#xD;
             program, and any weight loss supplements, during the study period.&#xD;
&#xD;
         10. Subjects must be able and willing to avoid anticoagulation (aspirin, warfarin,&#xD;
             heparin, rivaroxaban) for 1 week prior to each study treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of treatment for inner thigh fat, including cryolipolysis, noninvasive body&#xD;
             contouring or liposuction in the last year&#xD;
&#xD;
          2. Previous trauma or surgery to pelvis or thighs&#xD;
&#xD;
          3. Subjects with an unstable medical condition, as deemed by the investigator&#xD;
&#xD;
          4. Women who are pregnant or lactating or plan to become pregnant during the study period&#xD;
&#xD;
          5. Lymphedema or edema of thigh&#xD;
&#xD;
          6. Excessive skin laxity in the treatment area, as judged by the investigator&#xD;
&#xD;
          7. Severe thigh cellulite&#xD;
&#xD;
          8. Subjects with any disease in the treatment area, such as dermatologic disease, that&#xD;
             may be exacerbated by the study treatment&#xD;
&#xD;
          9. Subjects with any condition that may impair the evaluation of inner thigh fat&#xD;
&#xD;
         10. Subjects with known bleeding diathesis&#xD;
&#xD;
         11. Subjects with any known hypersensitivity to Kybella (deoxycholic acid) or any of the&#xD;
             inactive ingredients: benzyl alcohol, dibasic sodium phosphate, sodium chloride,&#xD;
             sodium hydroxide, hydrochloric acid&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arisa Ortiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2019</study_first_posted>
  <results_first_submitted>July 11, 2020</results_first_submitted>
  <results_first_submitted_qc>October 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 13, 2020</results_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Arisa Ortiz</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deoxycholic Acid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT04054011/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>No significant events pertaining to pre-assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Deoxycholic Acid</title>
          <description>Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)&#xD;
Deoxycholic Acid: Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>COVID</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Deoxycholic Acid</title>
          <description>Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)&#xD;
Deoxycholic Acid: Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="22" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24" lower_limit="19.7" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Any adverse event (AE) ascertained by patient report or physician evaluation&#xD;
One or more serious adverse events (SAE) as defined by CTCAEv4&#xD;
Adverse events leading to study drug discontinuation.</description>
        <time_frame>Baseline to 12 weeks after last treatment</time_frame>
        <population>AE in number of participants</population>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid</title>
            <description>single arm study without comparison</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Any adverse event (AE) ascertained by patient report or physician evaluation&#xD;
One or more serious adverse events (SAE) as defined by CTCAEv4&#xD;
Adverse events leading to study drug discontinuation.</description>
          <population>AE in number of participants</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ransient subcutaneous nodules</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>injection-site urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temporary numbness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Thigh Circumference Change</title>
        <description>change in thigh circumference as measured by tape measure</description>
        <time_frame>Baseline to 12 weeks after last treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid</title>
            <description>single arm study without comparison</description>
          </group>
        </group_list>
        <measure>
          <title>Thigh Circumference Change</title>
          <description>change in thigh circumference as measured by tape measure</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>average change from baseline at 4 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>average change from baseline at 12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Upper Inner Thigh Skin Fold Thickness Change</title>
        <description>change in upper inner thigh skin fold thickness as measured by body fat calipers</description>
        <time_frame>Baseline to 12 weeks after last treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid</title>
            <description>single arm study without comparison</description>
          </group>
        </group_list>
        <measure>
          <title>Upper Inner Thigh Skin Fold Thickness Change</title>
          <description>change in upper inner thigh skin fold thickness as measured by body fat calipers</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>average change from baselineat 4 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>average change from baseline at 12 week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Thigh Gap</title>
        <description>Thigh gap,&quot; measured with a handheld soft ruler, was defined as the horizontal distance between baseline &quot;sites of maximum bulge,&quot; with feet at standardized distance apart.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid ?Placebo</title>
            <description>Deoxycholic acid / Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Thigh Gap</title>
          <description>Thigh gap,&quot; measured with a handheld soft ruler, was defined as the horizontal distance between baseline &quot;sites of maximum bulge,&quot; with feet at standardized distance apart.</description>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Accuracy by Three Blinded Physicians in Correctly Identifying Before-and-after Photographs</title>
        <description>3 blinded physicians identified the before and after photos and the percentage number was 83% for percent accuracy of the results. The percent accuracy was calculated for the entire Arm/Group rather than for each participant</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Deoxycholic Acid</title>
            <description>Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)&#xD;
Deoxycholic Acid: Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Accuracy by Three Blinded Physicians in Correctly Identifying Before-and-after Photographs</title>
          <description>3 blinded physicians identified the before and after photos and the percentage number was 83% for percent accuracy of the results. The percent accuracy was calculated for the entire Arm/Group rather than for each participant</description>
          <units>percent accuracy of post treatment photo</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the entire study duration (up to 12 weeks after last treatment, or up to 9 months).</time_frame>
      <desc>Does not differ from clinicaltrials.gov. since this is a local treatment with minimal to no systemic affects, there is no risk of mortality to subjects. Subjects may experience adverse events described in the study description.</desc>
      <group_list>
        <group group_id="E1">
          <title>Deoxycholic Acid</title>
          <description>Deoxycholic acid (Kybella) 10 mg/ mL will be injected subcutaneously, targeting the medial thigh deep fat compartment (pre-fascial). Subjects will receive deoxycholic acid 2 mg/ cm2, with injections of 0.2 mL spaced evenly 1 cm apart within the treatment area. Bilateral thighs will be treated. Each treatment will consist of a maximum of 8 mL (40 injection sites) of the study drug, with a maximum of 4 mL (20 injection sites) of the study drug for each thigh. Subjects will undergo 1-4 treatment sessions, each treatment session separated by 6 weeks +/- 1 week (Treatment #2, #3, or #4 will be pursued if patient desires more treatment, and if there is sufficient fat for treatment, per investigator's judgment.)&#xD;
Deoxycholic Acid: Deoxycholic acid (Kybella) 10 mg/ mL subcutaneous</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>swelling</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>erythema</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>bruising</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the COVID-19 pandemic, three subjects could not complete their 12-week follow-up visits.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Joyce Yuan, MD</name_or_title>
      <organization>UCSD Dermatology</organization>
      <phone>(858) 657-8322</phone>
      <email>joyce.yuan2@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

